CV Therapeutics Announces Presentations at American Heart Association Scientific Ses...( PALO ALTO Calif. Oct. 23 /- CV Th...)

PALO ALTO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that multiple abstracts, including data from a prospectively identified analysis of patients with diabetes in the MERLIN TIMI-36 study, have been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2007, which will be held in Orlando, FL on November 4 - 7, 2007.

Ranexa(R) (ranolazine extended-release tablets):

Prospective Evaluation of the Prognostic Implications of Low Level Elevation of Cardiac Troponin Using a New Highly-sensitive Assay for Cardiac Troponin I: Results from the MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007, 9:30 a.m. EST

B-type Natriuretic Peptide and the Effect of Ranolazine in Patients with Non- ST Elevation Acute Coronary Syndromes in the MERLIN TIMI-36 Trial; Oral abstract, Monday, November 5, 2007, 10:00 a.m. EST

Anti-Ischemic Effects of Ranolazine in Women: Results from the Randomized, Placebo-controlled MERLIN TIMI-36 Trial; Oral abstract, Tuesday, November 6, 2007, 10:00 a.m. EST

Effect of Ranolazine on Hemoglobin A1c in the MERLIN TIMI-36 Randomized Controlled Trial; Oral abstract, Tuesday, November 6, 2007, 11:00 a.m. EST

Baseline Clinical Risk and Recurrent Ischemia as Detected on Continuous ECG (CECG) Monitoring in Patients with non-ST-Elevation Acute Coronary Syndrome in the MERLIN TIMI-36 Trial; Poster, Wednesday, November 7, 2007, 9:30 - 11:00 a.m. EST

Tecadenoson

Ventricular Rate Control Using the Adenosine Receptor Agonist CVT 510 in the Goat Model of Atrial Fibrillation: Efficacy During Exercise and Synergistic Effects with Metoprolol; Oral abstract, Tuesday, November 6, 2007, 4:15
'/>"/>